{"title":"拜耳和Evotec合作开发三种子宫内膜异位症候选药物","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i10.1820","DOIUrl":null,"url":null,"abstract":"Bayer Pharma and Evotec have entered into a 5-year partnership aimed at developing three clinical candidates for the treatment of endometriosis. Both companies will contribute drug targets and will be jointly responsible for early research and preclinical characterisation. Bayer will then undertake any subsequent clinical development and commercialisation. Bayer already markets the progesterone receptor agonist Visanne® (dienogest) for the treatment of endometriosis and the deal could help strengthen the company’s women’s healthcare business in the long term.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bayer and Evotec Collaborate to Develop Three Endometriosis Drug Candidates\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2012i10.1820\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bayer Pharma and Evotec have entered into a 5-year partnership aimed at developing three clinical candidates for the treatment of endometriosis. Both companies will contribute drug targets and will be jointly responsible for early research and preclinical characterisation. Bayer will then undertake any subsequent clinical development and commercialisation. Bayer already markets the progesterone receptor agonist Visanne® (dienogest) for the treatment of endometriosis and the deal could help strengthen the company’s women’s healthcare business in the long term.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2012i10.1820\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2012i10.1820","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Bayer and Evotec Collaborate to Develop Three Endometriosis Drug Candidates
Bayer Pharma and Evotec have entered into a 5-year partnership aimed at developing three clinical candidates for the treatment of endometriosis. Both companies will contribute drug targets and will be jointly responsible for early research and preclinical characterisation. Bayer will then undertake any subsequent clinical development and commercialisation. Bayer already markets the progesterone receptor agonist Visanne® (dienogest) for the treatment of endometriosis and the deal could help strengthen the company’s women’s healthcare business in the long term.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
